



1 Synthesis of Some Substituted Pyrimidines Derived from 3-Acetyl Coumarin

2 QASSIM A.H. JABER and NABEEL A.A. AL-RADHA*

3 Department of Chemistry, College of Education, Al-Qadisiyah University, Iraq

4 *Corresponding author: Tel: +964 7903620810; E-mail: nabeel1959@yahoo.com; khalidke_1962@yahoo.com

(Received: ; Accepted:) AJC-0000


5 The research work conducted during this study targets mainly the synthesis of a number of derivatives of coumarin containing ring
6 pyrimidin-2-one substitutes different aromatic rings, taking advantage of the Biginelli reaction which includes the reaction of (3-acetyl
7 coumarin) with suitable aromatic aldehydes and urea at the presence of AlCl_3 and ethanol absolute as a solvent. It has been indicated
8 various scientific journals that have been referenced to the presence of biological activity is important and diverse to these kinds of
9 compounds, which is the preparation of compound 3-acetyl coumarin (7) to be used as a compound base. The compounds created
10 heterocyclic are expected to have various important biological and therapeutic applications. This proves structural formulas for each of
11 new synthetic compounds on the basis of chemical reactions, rigorous analysis of the elements, the spectra infrared (FT-IR) and nuclear
12 magnetic resonance of the (^1H NMR and ^{13}C NMR), in addition to various physical available means means.

13 **Keywords:** Coumarin derivatives, Pyrimidines substituted, 4,3-Dihydro-(4-aryl-6-coumarin)pyrimidin-2-one.


INTRODUCTION

14 Coumarin derivatives received considerable attention by
15 researchers as one of the compounds that possess medical and
16 biological activities as well as industrial uses, where many of
17 the products that contain coumarin units showed a various of
18 pharmacological activities¹⁻⁴. It is also found that compounds
19 containing pyrimidine ring play an important role in many
20 biological systems such as vitamins, enzymes assistance and
21 many antibiotics as well as its presence in the nucleic acids⁵,
22 which attracted multiple biological activities of compounds
23 pyrimidine much attention in the past few years, so the researchers
24 worked hard in the preparation of these compounds because
25 of its great diversity in the effectiveness of biological and
26 pharmaceutical criteria⁶. The pyrimidine derivatives are major
27 elements of a large number of pharmaceutical manufactured
28 which show a group of derivatives pyrimidine activity as anti-
29 microbial⁸, analgesic, antiviral, anti-inflammatory⁹, also anti-
30 HIV¹⁰, anti-tubercular¹¹, anti-tumor¹², anti-malarial¹³ and
31 diuretic¹⁴, in addition to the pyrimidine compounds are also
32 used as hypnotic drugs for the nervous system¹⁵. It can also
33 prepare this type of compounds through a various of ways
34 and Biginelli reaction¹⁶ of the most important ways used for
35 the preparation of this type of compounds, which includes
36 this reaction blending ethyl acetoacetate (1) or its derivatives
37 with benzaldehyde (2) or its derivatives, urea (3) and that the
38 process occurs, the reaction is heating mixture of the three

39 components dissolved in the solvent particularly with the
40 availability of acidic conditions to produce through this method
41 new derivatives pyrimidine known as 4,3-dihydro-pyrimidin-
42 2-one (4) as shown in the following equation:



43 Uracil is a very important class of pyrimidine derivatives^{17a},
44 where exhibit various pharmacological and biological
45 activity^{17b}, for example, fluorouracil (5) is used widely as an
46 anti-cancer¹⁸. While the compound 5-nitouracil (6) used to
47 inhibition of the enzyme thymidine phosphorylase¹⁹ and also
48 its derivative showed antibacterial activity²⁰. Also 5-cinnamoyl-
49 6-aminouracil (7) derivatives are used as agents inhibition
50 against the growth of cancer cells²¹. While 6-aminouracils (8)
51 find wide application as starting materials for the preparation
52 of many of the active compounds and biologically important
53 as well as, its derivatives can be used as a coupling component
54 in dye chemistry²². In addition to the above mentioned proper-
55 ties, it was prepared a series of coumarin derivatives containing
56 on pyrimidine ring (Scheme-I) and so by taking advantage of
57 Biginelli condensing²³.



EXPERIMENTAL

58 **General experimental procedures:** The chemicals used
59 in the synthesis of all compounds were purchased from Aldrich,
60 Merck and BDH Chemical Companies and used without further
61 purification. The melting points were measured on an Electro-
62 thermal Melting point/SMP (Gallenkamp) and are uncorrected.

63 Either devices used in the spectral measurements are: (1)
64 Infrared spectroscopy of type FT-IR spectrophotometer
65 (Shimadzu), where KBr tablet used as a reference for those
66 measurements. (2) Nuclear magnetic resonance spectroscopy
67 of the proton and carbon-type Biospin Avance III and 400
68 MHz (Germany) 600 MHz using (DMSO-*d*₆) as solvent and
69 TMS as a reference.

70 Either thin layer chromatography (TLC) was performed
71 on Alumina plates covered with silica gel layer and the spots
72 were developed with iodine vapour. Elemental analyses (CHN)
73 were carried out by using Vario Elemental Analyzer 3000
74 (Shimadzu, Japan).

75 **Synthesis of compound 3-acetyl coumarin²⁴ (7):** Added
76 (12.21 g/0.1 mol) of salicylaldehyde to (13.0 g/0.1 mol) of ethyl
77 acetoacetate, then put the mixture in a beaker capacity (100
78 mL) containing (10 mL) ethanol absolute and then was added
79 (5) drops from catalyst (piperidine), the mixture was rapid
80 stirred for 0.5 h at 5-10 °C. The yellow solid separated was
81 filtered off subsequently washed with ethanol, dried and
82 recrystallized from ethanol to give 3-acetyl coumarin as yellow
83 crystals. Yield: 15.7 g (83 %), m.p. = 120-122 °C (sawn 119-
84 121 °C), *R*_f = 0.42.

85 **Preparation of a series of compounds 3,4-dihydro(4-
86 aryl-6-coumarin)pyrimidin-2-one²³ (8-13):** A solution of 3-
87 acetyl coumarin (5 mmol) in ethanol absolute (20 mL) contains
88 AlCl₃ (10 mol %) was refluxed with the appropriate substituted
89 benzaldehyde (5 mmol) and urea (4 mmol) for about 8-12 h.
90 The progress of reaction was monitored by TLC. After the
91 completion of reaction, the reaction mixture was allowed to
92 reach ambient temperature and then the precipitate formed
93 was filtered, washed with water, dried and recrystallized from
94 ethanol to get pure powder.

95 **Synthesis of 3,4-dihydro-4-(4-hydroxyphenyl)-6-(2-oxo-
96 2H-chromen-3-yl)pyrimidin-2(1H)-one (8):** The compound
97 **8** was prepared according to general method where taking (0.56
98 g, 3 mmol) of compound **7** with (0.36 g, 3 mmol) of 4-hydroxy-
99 benzaldehyde and (0.24 g, 4 mmol) of urea. After reflux the mix
100 for 10 h, the compound was obtained **8** as brown precipitate,

after recrystallization. Yield: 0.65 g (64 %), m.p. = 193-195 °C, 101
*R*_f = 0.66. Anal. calcd. (%) for C₁₉H₁₄N₂O₄ (334.33): C, 68.26; 102
H, 4.22; N, 8.38. Found (%): C, 67.96; H, 4.12; N, 8.11. 103

104 **Synthesis of 3,4-dihydro-4-(4-methoxyphenyl)-6-(2-oxo-
105 2H-chromen-3-yl)pyrimidin-2(1H)-one (9):** The
106 compound **9** was prepared according to general method where
107 taking (0.56 g, 3 mmol) of compound **7** with (0.4 g, 3 mmol)
108 of 4-methoxybenzaldehyde and (0.24 g, 4 mmol) of urea. After
109 reflux the mix for 8.5 h. The compound was obtained compound
110 **9** as reddish brown precipitate, after recrystallization.
111 Yield: 0.62 g (59 %), m.p. = 117-119 °C, *R*_f = 0.64. Anal.
112 calcd. (%) for C₂₀H₁₆N₂O₄ (348.35): C, 68.96; H, 4.63; N, 8.04.
113 Found (%): C, 68.72; H, 4.48; N, 7.85.

114 **Synthesis of 3,4-dihydro-4-(4-chlorophenyl)-6-(2-oxo-
115 2H-chromen-3-yl)pyrimidin-2(1H)-one (10):** The compound
116 **10** was prepared according to general method where taking
117 (0.56 g, 3 mmol) of compound **7** with (0.42 g, 3 mmol) of 4-
118 chlorobenzaldehyde and (0.24 g, 4 mmol) of urea. After reflux
119 in the mixture for 11 h, the compound was obtained compound
120 **10** as brown precipitate, after recrystallization. Yield: 0.74 g
121 (69 %), m.p. = 241-243 °C, *R*_f = 0.56. Anal. calcd. (%) for
122 C₁₉H₁₃N₂O₃Cl (352.77): C, 64.69; H, 3.71; N, 7.94. Found (%):
123 C, 64.41; H, 3.56; N, 7.73.


124 **Synthesis of 3,4-dihydro-4-(2,4-dichlorophenyl)-6-(2-oxo-
125 2H-chromen-3-yl)pyrimidin-2(1H)-one (11):** The
126 compound **11** was prepared according to general method where
127 taking (0.56 g, 3 mmol) of compound **7** with (0.52 g, 3 mmol)
128 of 2,4-dichlorobenzaldehyde and (0.24 g, 4 mmol) of urea. After
129 reflux the mix for 9 h, the compound was obtained compound
130 **11** as white precipitate, after recrystallization. Yield: 0.68 g
131 (58 %), m.p. = 263-265 °C, *R*_f = 0.62. Anal. calcd. (%) for
132 C₁₉H₁₂N₂O₃Cl₂ (387.22): C, 58.93; H, 3.12; N, 7.23. Found
133 (%): C, 58.72; H, 2.94; N, 7.07.

134 **Synthesis of 3,4-dihydro-4-(4-bromophenyl)-6-(2-oxo-
135 2H-chromen-3-yl)pyrimidin-2(1H)-one (12):** The compound
136 **12** was prepared according to general method where taking
137 (0.56 g, 3 mmol) of compound **7** with (0.55 g, 3 mmol) of 4-
138 bromobenzaldehyde and (0.24 g, 4 mmol) of urea. After reflux
139 the mix for 12 h. Was obtained compound **12** as brown precipi-
140 tate, after recrystallization. Yield: 0.72 g (60 %), m.p. = 237-
141 239 °C, *R*_f = 0.45. Anal. calcd. (%) for C₁₉H₁₃N₂O₃Br (397.22):
142 C, 57.45; H, 3.30; N, 7.05. Found (%): C, 57.32; H, 3.14; N,
143 6.84.

144 **Synthesis of 3,4-dihydro-4-(4-bromophenyl)-6-(2-oxo-
145 2H-chromen-3-yl)pyrimidin-2(1H)-one (13):** The compound
146 **13** was prepared according to general method where taking
147 (0.56 g, 3 mmol) of compound **7** with (0.44 g, 3 mmol) of 4-
148 bromobenzaldehyde and (0.24 g, 4 mmol) of urea. After reflux
149 the mix for 9 h. Was obtained compound **13** as greenish yellow
150 precipitate, after recrystallization. Yield: 0.67 g (62 %), m.p.
151 = 209-211 °C, *R*_f = 0.54. Anal. calcd. (%) for C₂₁H₁₉N₃O₄
152 (361.39): C, 69.79; H, 5.30; N, 11.63. Found (%): C, 69.58;
153 H, 5.16; N, 11.47.


RESULTS AND DISCUSSION

The synthetic strategies adopted in the synthesis of the 154
intermediate and target compounds are depicted in the **Scheme-** 155
I. The base compound 3-acetyl coumarin **7** was prepared from 156




Scheme-I: Synthetic pathway for the compounds 7-13 and their structures

157 reaction of salicylaldehyde with ethyl acetoacetate and a few
158 drops of piperidine as catalyst and ethanol as solvent according
159 to the following equation:




160 The structure compound 7 was determined on the basis
161 of spectral data, as well as elemental analysis, according to
162 the literature²⁵.

163 Coumarin derivatives (8-13) were synthesized through of
164 condensation 3-acetyl coumarin (7) with number of substituted
165 aromatic aldehydes and urea with a small amount of AlCl₃ as
166 catalyst and ethanol absolute as solvent. According to the
167 following equation:



(7)



(8-13)


R = 8: 4-OH, 9: 4-OMe, 10: 4-Cl, 11: 2,4-(Cl)₂,
12: 4-Br, 13: 4-N(CH₃)₂

The mechanism proposed for this reaction includes two 168
steps²⁶: The first aldol condensation between benzaldehyde and 169
methyl group to form a stabilized carbenium ion. A second 170
step is the nucleophilic addition of urea gives the intermediate, 171
which quickly dehydrates to give the desired product (**Scheme-** 172
II). 173

The melting point was uncorrected which determined by 174
open capillary tube and was listed in the Table-1 as well as 175
other Physical properties. The synthesized compounds were 176
characterized by their elemental analysis, IR, ¹H NMR, ¹³C 177
NMR. The IR spectra of the compounds 8-13 showed charac- 178
teristic absorption bands at 3440-3172 cm⁻¹ (OH; NH) stretching, 179
1751-1712 cm⁻¹ due to (lactone C=O) and 1697-1643 cm⁻¹ 180
attributed to the (amid C=O) stretching vibration. The absorp- 181
tion band seen at a 1596-1565 cm⁻¹ could be attributed to the 182
(C=C) stretching and other absorption bands was listed in 183
Table-2. The ¹H NMR spectra of the compounds 8-13 showed 184
singlet in the range 11.18-9.81 ppm, which is characteristic 185
for N-H and singlet in the range 9.01-8.22 ppm due to H-4 for 186
coumarin, as well as aromatic protons which is showed at range 187
7.98-7.00 ppm and other singles were listed in the Table-3. 188
The ¹³C NMR spectra of the compounds 8-13 showed singlet 189

TABLE-1
PHYSICO-CHEMICAL DATA OF THE COMPOUNDS 8-13

Comp. No.	R	m.p. (°C)	Yield (%)	Colour	R _f
8	OH-4	193-195	64	Brown powder	0.66
9	OMe-4	217-219	59	Reddish brown	0.70
10	4-Cl	241-243	69	Brown powder	0.56
11	2,4-Di(Cl)	263-265	58	White powder	0.62
12	4-Br	237-239	60	Brown powder	0.45
13	4-N(CH ₃) ₂	209-211	62	Powder yellow	0.52



[79]=R=4-OH, [80]=R=4-OMe, [81]=R=4-Cl, [82]=R=2,4-(Cl)₂, [83]=R=4-Br, [84]=R=4-N(CH₃)₂

Scheme-II

TABLE-2
FT-IR SPECTRA DATA OF THE COMPOUNDS 8-13

Comp. No.	KBr, ν_{\max} , cm^{-1}					
	N-H	C-H aromatic	C=O lactone	C=O amide	C=C Olfe.	Other
8	3386	3070	1725	1697	1565	OH 3440
9	3326	3039	1720	1676	1573	O-CH ₃ 1056
10	3354	3018	1743	1687	1567	C-Cl 726
11	3332	3008	1751	1650	1589	C-Cl 640, 684
12	3178	3024	1720	1650	1596	C-Br 663
13	3201	3070	1712	1643	1593	-

TABLE-3
¹H NMR SPECTRA DATA OF THE COMPOUNDS 8-13

Comp. No.	¹ H NMR (ppm)					
	H-4 coumarin	H-5' pyrimidine	Ar-H	N-H (2H)d	H-4' pyrimidine	Other
8	8.79	8.07	7.98-7.16	6.86	6.74	OH 5.27
9	8.67	7.97	7.80-7.01	6.90	6.11	O-CH ₃ 3.87
10	8.72	8.52	7.38-7.23	6.81	5.83	-
11	8.79	8.75	7.65-7.17	6.96	5.93	-
12	8.22	8.19	8.08-7.67	6.44	5.58	-
13	9.01	8.27	7.71-7.00	96.6	5.93	N-(CH ₃) ₂ 3.22

TABLE-4
¹³C NMR SPECTRA DATA OF THE COMPOUNDS 8-13

Comp. No.	C=O lactone	C=O amide	C4"-arom. phenyl	C8a coum.	C1"-arom. phenyl	C-arom.	C5'-pyri.	C4'-pyri.	Other
8	167.75	158.12	158.93	157.67	154.92	134.6-116.6	116.33	64.95	–
9	165.45	157.56	157.52	160.80	139.26	133.3-118.2	112.58	61.15	OMe 60.42
10	162.43	160.02	137.63	154.34	149.18	134.5-116.6	112.86	81.22	–
11	164.58	156.71	150.12	150.90	150.82	139.6-119.7	116.29	85.44	–
12	162.24	157.85	142.70	156.62	145.97	132.9-118.8	115.20	56.70	–
13	162.05	156.88	150.62	153.25	146.02	137.6-128.3	108.4	62.05	N(CH ₃) ₂ 40.05

190 in the range 167.75-162.05 ppm which is characteristic of
 191 (lactone C=O) and singlet in the range 160.02-156.71 ppm
 192 attributed to (amid C=O), as well as aromatic atoms carbon
 193 which is showed at range 139.6-116.06 ppm and other singles
 194 were listed in the Table-4. Either elemental analysis (C-H-N)
 195 was listed in the Table-5.

TABLE-5
 C-H-N SPECTRA DATA OF THE COMPOUNDS 8-13

Comp. No.	Elemental analysis (%): Calcd. (Found)		
	C	H	N
8	68.26 (67.96)	4.22 (4.12)	8.38 (8.11)
9	68.96 (68.72)	4.63 (4.48)	8.04 (7.85)
10	64.69 (64.41)	3.71 (3.56)	7.94 (7.73)
11	58.93 (58.72)	3.12 (2.94)	7.23 (7.07)
12	57.45 (57.32)	3.30 (3.14)	7.05 (6.84)
13	69.79 (69.58)	5.30 (5.16)	11.63 (11.47)

ACKNOWLEDGEMENTS

196 I am extremely thankful to Prof. Dr. Najim A. Al-Masoudi
 197 for providing all facilities and conducting spectral measurements
 198 and their interpretation and encouragement for successful
 199 completion of this work.

REFERENCES

1. E.A. Gunnewegh, A.J. Hoefnagel, R.S. Downing and H. van Bekkum, *Recl. Trav. Chim. Pays Bas*, **115**, 226 (1996).
2. W.-C. Sun, K.R. Gee and R.P. Haugland, *Bioorg. Med. Chem. Lett.*, **8**, 3107 (1998).
3. J. Oyamada, C. Jia, Y. Fujiwara and T. Kitamura, *Med. Chem. Lett.*, **14**, 380 (2002).
4. R.D.H. Murray, J. Medez and S.A. Brown, *The Natural Coumarins: Occurrence, Chemistry and Biochemistry*, Wiley, New York, p. 68 (1982).
5. F. Hueso-Ureña, N.A. Illán-Cabeza, M.N. Moreno-Carretero, J.M. Martínez-Martos and M.J. Ramírez-Expósito, *J. Inorg. Biochem.*, **94**, 326 (2003).
6. H.S. Basavaraja, K.V. Jayadevaiah and M.M. Hussain, *J. Pharm. Sci. Res.*, **12**, 5 (2010).
7. R. Patel, K. Desai and J. Chikhaliya, *Ind. Chem. Soc.*, **80**, 138 (2003).
8. K. Desai, R. Patel and K. Chikhaliya, *J. Ind. Chem.*, **45**, 773(2006).
9. A.E.-G.E. Amr, N.M. Sabry and M.M. Abdulla, *Monatsh. Chem.*, **138**, 699 (2007).
10. N. Fujiwara, T. Nakajima, Y. Ueda, H. Fujita and H. Kawakami, *Bioorg. Med. Chem.*, **16**, 9804 (2008).
11. L. Ballell, R.A. Field, G.A.C. Chung and R.J. Young, *Bioorg. Med. Chem. Lett.*, **17**, 1736 (2007).
12. E. Wagner, K. Al-Kadasi, M. Zimecki and W. Sawka-Dobrowolska, *Eur. J. Med. Chem.*, **43**, 2498 (2008).
13. K. Gorlitzer, S. Herbig and R.D. Walter, *J. Pharm. Res.*, **52**, 670 (1997).
14. I.V. Ukrainets, I.A. Tugaibei, N.L. Bereznyakova, V.N. Kravchenko and A.V. Turov, *Chem. Heterocycl. Compd.*, **44**, 565 (2008).
15. S.Q. Wang, L. Fang, X.J. Liu and K. Zhao, *Chin. Chem. Lett.*, **15**, 885 (2004).
16. C.O. Kappe, *Tetrahedron*, **49**, 6937 (1993).
17. Wamhoff, Dzenis and K. Hirota, *J. Adv. Heterocyclic Chem.*, **55**, 129 (1992); Z. SeferoÄŸlu, *ARKIVOC*, **7**, 42 (2009).
18. P.G. Ellis, *The Chemistry of Heterocyclic Dyes*; E.C. Taylor, Editor; Wiley Interscience: Chichester; **47**; pp. 1-20 (1987).
19. E. Coats, W.R. Glave and C. Hansch, *J. Med. Chem.*, **13**, 913 (1970).
20. B.H. Lee, J.H. Shin and M.K. Lim, *Bull. Korean Chem. Soc.*, **18**, 734 (1997).
21. J.L. Bernier, J.P. Henichart, V. Warin, C. Trentesaux and J.C. Jardillier, *J. Med. Chem.*, **28**, 497 (1985).
22. A.R. Katritzky and C.W. Rees, "Comprehensive Heterocyclic Chemistry", 3rdEd., Pergamon Press: Oxford, pp. 57,(1984).
23. S. Anil and K. Sanjay, *Indian J. Chem.*, **46B**, 1690 (2007).
24. HaiderK, A.Al-chriti, *MS.C.thesis*, Al-Kufa university, (2013).
25. B.S. Jayashree, S. Arora and K.N. Venugopala, *Asian J. Chem.*, **20**, 1 (2008).
26. F. Sweet and J.D. Fissekis, *J. Am. Chem. Soc.*, **95**, 8741 (1973).